50-year Wall Street legend: “Sell this tech stock NOW”

Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.

You can watch for it for free, right here.

Sally Susman Biography and Net Worth

Insider of Pfizer

Sally Susman is Executive Vice President and Chief Corporate Affairs Officer at Pfizer. She is vice chair of the Pfizer Foundation and co-chair of Pfizer’s Political Action Committee.

Sally leads engagement with all of Pfizer’s external stakeholders overseeing communications, corporate responsibility, global policy, government relations, investor relations and patient advocacy. Before joining Pfizer in 2007, Sally held several senior communications and government relations roles at Estée Lauder Companies and the American Express Company. Earlier in her career, she spent eight years in government service focused on international trade issues.

Sally serves on the board of WPP plc, a world leader in advertising and marketing based in the U.K., and as co-chair of the board of The International Rescue Committee. She is also a member of the Council on Foreign Relations.

What is Sally Susman's net worth?: The estimated net worth of Sally Susman is at least $3.98 million as of July 20th, 2018. Ms. Susman owns 155,377 shares of Pfizer stock worth more than $3,982,313 as of November 23rd. This net worth approximation does not reflect any other investments that Ms. Susman may own. Learn More about Sally Susman's net worth.
How do I contact Sally Susman?: The corporate mailing address for Ms. Susman and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Sally Susman's contact information.
Has Sally Susman been buying or selling shares of Pfizer?: Sally Susman has not been actively trading shares of Pfizer during the past quarter. Most recently, Sally Susman sold 40,381 shares of the business's stock in a transaction on Friday, July 20th. The shares were sold at an average price of $37.22, for a transaction totalling $1,502,980.82. Following the completion of the sale, the insider now directly owns 155,377 shares of the company's stock, valued at $5,783,131.94. Learn More on Sally Susman's trading history.
Who are Pfizer's active insiders?: Pfizer's insider roster includes Ronald Blaylock (Director), Albert Bourla (DVM), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Albert D.V.M. (DVM), Frank Damelio (EVP), Frank D'Amelio (CFO & Exec. VP ), Jennifer Damico (SVP), Jennifer Damico (SVP), Scott Gottlieb (Director), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.
Are insiders buying or selling shares of Pfizer?: In the last year, Pfizer insiders bought shares 2 times. They purchased a total of 4,000 shares worth more than $107,650.00. The most recent insider tranaction occured on October, 30th when Director Scott Gottlieb bought 1,000 shares worth more than $28,240.00. Insiders at Pfizer own 0.1% of the company. Learn More about insider trades at Pfizer.
Information on this page was last updated on 10/30/2024.

Sally Susman Insider Trading History at Pfizer

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/20/2018	Sell	40,381	$37.22	$1,502,980.82	155,377
2/27/2018	Sell	33,368	$37.03	$1,235,617.04	191,505
9/12/2017	Sell	38,230	$35.00	$1,338,050.00	145,649
5/5/2016	Sell	76,116	$33.75	$2,568,915.00	195,951
3/12/2015	Sell	46,179	$34.00	$1,570,086.00
3/4/2014	Sell	67,585	$32.59	$2,202,595.15	173,637

Sally Susman Buying and Selling Activity at Pfizer

Pfizer Company Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Today's Range

Now: $25.63

$25.10

$25.75

50 Day Range

MA: $28.21

$24.80

$30.20

2 Week Range

Now: $25.63

$24.48

$31.54

Volume

41,859,420 shs

Average Volume

38,489,203 shs

Market Capitalization

$145.24 billion

P/E Ratio

34.64

Dividend Yield

6.69%

Beta

0.67